Dec 05, 2022
|
Nakadai, T., Yang, L., Kumegawa, K. and Maruyama, R. Estrogen receptor α K303R mutation reorganizes its binding to forkhead box protein A1 regions and induces chromatin opening. Molecular biology reports, in press (2022)
|
Nov 08, 2022
|
Haga, Y., Yamada, M., Fujii, R., Saichi, N., Yokokawa, T., Hama, T., Hayakawa, Y. and Ueda, K. Fast and ultrasensitive glycoform analysis by supercritical fluid chromatography-tandem mass spectrometry. Anal. Chem., in press (2022)
|
Oct 28, 2022
|
Huang, S., Haga, Y., Li, J., Zhang, J., Kweon, H. K., Seino, J., Hirayama, H., Fujita, M., Moremaen, K., Andrews, P., Suzuki, T. and Wang, Y. Mitotic phosphorylation inhibits the Golgi mannosidase MAN1A1. Cell Rep., in press (2022)
|
Aug 23, 2022
|
Minegishi, Y., Kiyotani, K., Nemoto, K., Inoue, Y., Haga, Y., Fujii, R., Saichi, N., Nagayama, S. and Ueda, K. Differential ion mobility mass spectrometry in immunopeptidomics identifies neoantigens carrying colorectal cancer driver mutations. Commun. Biol., in press (2022)
|
Aug 23, 2022
|
Ochiai, R., Hayashi, K., Yamamoto, H., Fujii, R., Saichi, N., Shinchi, H., Ishida, T., Honda, T., Shimizu, T., Matsutani, N., Seki, N., Kawamura, M. and Ueda, K. Plasma exosomal DOK3 reflects immunological states in lung tumor and predicts prognosis of gefitinib treatment. Cancer Sci., in press (2022)
|
Aug 16, 2022
|
Namikawa, K., Tanaka, N., Ota, Y., Takamatsu, M., Kosugi, M., Tokai, Y., Yoshimizu, S., Horiuchi, Y., Ishiyama, A., Yoshio, T., Hirasawa, T., Amino, S., Furuya, R., Gotoh, O., Kaneyasu, T., Nakayama, I., Imamura, Y., Noda, T., Fujisaki, J. and Mori, S. Genomic features of Helicobacter pylori-naïve diffuse-type gastric cancer. J. Pathol., in press (2022)
|
Aug 16, 2022
|
Sakashita, T., Yanagitani, N., Koike, S., Low, S. K., Takagi, S., Baba, S., Takeuchi, K., Nishio, M., Fujita, N. and Katayama, R. Fibroblast growth factor receptor 3 overexpression mediates ALK inhibitor resistance in ALK-rearranged non-small cell lung cancer. Cancer Sci., in press (2022)
|
Jul 21, 2022
|
Fukuoka, M., Ichikawa, Y., Osako, T., Fujita, T., Baba, S., Takeuchi, K., Tsunoda, N., Ebata, T., Ueno, T., Ohno, S. and Saitoh, N. The ELEANOR noncoding RNA expression contributes to cancer dormancy and predicts late recurrence of estrogen receptor-positive breast cancer. Cancer Sci., in press (2022)
|
Jul 19, 2022
|
Igarashi, N., Miyata, K., Loo, T. M., Chiba, M., Hanyu, A., Nishio, M., Kawasaki, H., Zheng, H., Toyokuni, S., Kon, S., Moriyama, K., Fujita, Y. and Takahashi, A. Hepatocyte growth factor derived from senescent cells attenuates cell competition-induced apical elimination of oncogenic cells. Nat. Commun., in press (2022)
|
Jul 08, 2022
|
Kunimasa, K., Ikeda-Ishsikawa, C., Tani, Y., Tsukahara, S., Sakurai, J., Okamoto, Y., Koido, M., Dan, S. and Tomida, A. Spautin-1 inhibits mitochondrial complex I and leads to suppression of the unfolded protein response and cell survival during glucose starvation. Sci. Rep., 12, 11533 (2022)
|
Jun 21, 2022
|
Shimizu, Y., Maruyama, K., Suzuki, M., Kawachi, H., Low, S. K., Oh-Hara, T., Takeuch, K., Fujita, N., Nagayama, S. and Katayama, R. Acquired resistance to BRAF inhibitors is mediated by BRAF splicing variants in BRAF V600E mutation-positive colorectal neuroendocrine carcinoma. Cancer Lett., in press (2022)
|
Jun 20, 2022
|
Ebata, H., Loo, T. M. and Takahashi, A. Telomere maintenance and the cGAS-STING pathway in cancer. Cells, in press (2022)
|
Jun 20, 2022
|
Kumegawa, K., Takahashi, Y., Saeki, S., Yang, L., Nakadai, T., Osako, T., Mori, S., Noda, T., Ohno, S., Ueno, T. and Maruyama, R. GRHL2 motif is associated with intratumor heterogeneity of cis-regulatory elements in luminal breast cancer. NPJ Breast Cancer, 8, 70 (2022)
|
May 26, 2022
|
Ohta, K., Fushimi, T., Okamura, M., Akatsuka, A., Dan, S., Iwasaki, H., Yamashita, M. and Kojima, N. Structure–antitumor activity relationship of hybrid acetogenins focusing on connecting groups between heterocycles and the linker moiety. RSC Advances, 12, 15728-15739 (2022)
|
May 11, 2022
|
Moyret-Lalle, C., Prodhomme, M. K., Burlet, D., Kashiwagi, A., Petrilli, V., Puisieux, A., Seimiya, H. and Tissier, A. Role of EMT in the DNA damage response, double-strand break repair pathway choice and its implications in cancer treatment. Cancer Sci., in press (2022)
|
May 09, 2022
|
Tanaka, N., Mori, S., Kiyotani, K., Ota, Y., Gotoh, O., Kusumoto, S., Nakano, N., Suehiro, Y., Ito, A., Choi, I., Ohtsuka, E., Hidaka, M., Nosaka, K., Yoshimitsu, M., Imaizumi, Y., Iida, S., Utsunomiya, A., Noda, T., Nishikawa, H., Ueda, R. and Ishida, T. Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia/lymphoma. Haematologica, in press (2022)
|
May 06, 2022
|
Adachi, J., Kakudo, A., Takada, Y., Isoyama, J., Ikemoto, N., Abe, Y., Narumi, R., Muraoka, S., Gunji, D., Hara, Y., Katayama, R. and Tomonaga, T. Systematic identification of ALK substrates by integrated phosphoproteome and interactome analysis. Life Sci. Alliance, 5, e202101202 (2022)
|
Apr 08, 2022
|
Matsumori, H., Watanabe, K., Tachiwana, H., Fujita, T., Ito, Y., Tokunaga, M., Sakata-Sogawa, K., Osakada, H., Haraguchi, T., Awazu, A., Ochiai, H., Sakata, Y., Ochiai, K., Toki, T., Ito, E., Goldberg, I. G., Tokunaga, K., Nakao, M. and Saitoh, N. Ribosomal protein L5 facilitates rDNA-bundled condensate and nucleolar assembly. Life science alliance, 5, e202101045 (2022)
|
Apr 06, 2022
|
Takemoto, A., Takagi, S., Ukaji, T., Gyobu, N., Kakino, M., Takami, M., Kobayashi, A., Lebel, M., Kawaguchi, T., Sugawara, M., Tsuji-Takayama, K., Ichihara, K., Funauchi, Y., Ae, K., Matsumoto, S., Sugiura, Y., Takeuchi, K., Noda, T., Katayama, R. and Fujita, N. Targeting podoplanin for the treatment of osteosarcoma. Clin. Cancer Res., in press (2022)
|
Mar 18, 2022
|
Shimizu, Y., Okada, K., Adachi, J., Abe, Y., Narumi, R., Uchibori, K., Yanagitani, N., Koike, S., Takagi, S., Nishio, M., Fujita, N. and Katayama, R. GSK3 inhibition circumvents and overcomes acquired lorlatinib resistance in ALK-rearranged non-small-cell lung cancer. NPJ Precis. Oncol., in press (2022)
|
Mar 08, 2022
|
Osako, T., Matsuura, M., Yotsumoto, D., Takayama, S., Kaneko, K., Takahashi, M., Shimazu, K., Yoshidome, K., Kuraoka, K., Itakura, M., Tani, M., Ishikawa, T., Ohi, Y., Kinoshita, T., Sato, N., Tsujimoto, M., Nakamura, S., Tsuda, H., Noguchi, S. and Akiyama, F. A prediction model for early systemic recurrence in breast cancer using a molecular diagnostic analysis of sentinel lymph nodes: A large-scale, multicenter cohort study. Cancer, in press (2022)
|
Mar 03, 2022
|
Tanimura, K., Yamada, T., Okada, K., Nakai, K., Horinaka, M., Katayama, Y., Morimoto, K., Ogura, Y., Takeda, T., Shiotsu, S., Ichikawa, K., Watanabe, S., Morimoto, Y., Iwasaku, M., Kaneko, Y., Uchino, J., Taniguchi, H., Yoneda, K., Matoba, S., Sakai, T., Uehara, H., Yano, S., Kusaba, T., Katayama, R. and Takayama, K. HER3 activation contributes toward the emergence of ALK inhibitor-tolerant cells in ALK-rearranged lung cancer with mesenchymal features. NPJ Precis Oncol, 6, 5 (2022)
|
Feb 16, 2022
|
Miyata, K. and Takahashi, A. Pericentromeric repetitive ncRNA regulates chromatin interaction and inflammatory gene expression. Nucleus, 13, 74-78 (2022)
|
Feb 14, 2022
|
Yoshida, Y., Yuki, K., Dan, S., Yamazaki, K. and Noda, M. Suppression of tumor metastasis by a RECK-activating small molecule. Sci. Rep., 12, 2319 (2022)
|
Feb 14, 2022
|
Haga, Y. and Ueda, K. Glycosylation in cancer: its application as a biomarker and recent advances of analytical techniques. Glycoconj J, in press (2022)
|
Jan 04, 2022
|
Sagawa, R., Sakata, S., Gong, B., Seto, Y., Takemoto, A., Takagi, S., Ninomiya, H., Yanagitani, N., Nakao, M., Mun, M., Uchibori, K., Nishio, M., Miyazaki, Y., Shiraishi, Y., Ogawa, S., Kataoka, K., Fujita, N., Takeuchi, K. and Katayama, R. Soluble PD-L1 through alternative polyadenylation works as a decoy in lung cancer immunotherapy. JCI insight, in press (2021)
|